Advertisement
"We are very pleased to add a Board certified Oncologist of Dr. Bender'scaliber to our management team," said Dr. Sixt. "As we continue to expand ourU.S. presence and the use of our MammaPrint(R) diagnostic service by U.S.-based patients, we are confident that Dr. Bender's wealth of experience willplay a critical role in the company's strategic planning and execution of ourclinical programs."
Advertisement
"We are delighted to welcome Dr. Bender to the Agendia team," said Dr. JanGroen, chief operating officer (COO) of Agendia. "His reputation and broadexperience in the field of oncology, including treatment, drug development andgenomic assays, will be an extremely valuable asset to our company as weincrease our global presence."
"I am very excited to be joining Agendia at such a pivotal and excitingtime in the company's development," said Dr. Bender. "Their FDA clearedbreast cancer prognostic test MammaPrint clearly shows that Agendia isbecoming an important diagnostic provider for the management of breast cancer.The company's promising oncology pipeline and its depth of expertise showsthat the company is positioned very well to achieve its goal of bringinginnovative cancer diagnostics to patient care."
Most recently, Dr. Bender was vice president and chief medical officer atSpectrum Pharmaceuticals, Inc., an oncology drug development company based inIrvine, CA. Dr. Bender has held key positions in the healthcare industry,including medical director for the oncology division of Quest Diagnostics,Inc., where he was involved in the development of new biomarkers and genomicassays. Prior to his tenure at Quest, he spent nearly two decades at KaiserPermanente where he helped to develop their clinical oncology program.
Dr. Bender also served on the executive board of the San Diego Hospice andthe American Cancer Society, and as a clinical instructor at the University ofCalifornia, San Diego School of Medicine. He received his medical degree fromthe UCLA School of Medicine followed by specialty training in internalmedicine at UCLA-Harbor General Hospital. He did his sub-specialty trainingin hematology/ oncology at the National Cancer Institute, where he spent threeof his six years there as a senior investigator in the medicine branch.
Dr. Bender continues to serve as a clinical instructor at the Universityof California, Irvine School of Medicine, is a co-editor of the internationaloncology journal Anti-Cancer Drugs, and serves as an expert peer-reviewer inoncology for the Medical Board of California.
About Agendia BV
Agendia BV, located in Amsterdam, The Netherlands, is a world leader ingene expression analysis-based diagnostics. With three products on the marketand an expanding market base, the company focuses on the development andcommercialization of diagnostic tests using tumor gene expression profiling.Agendia was the first company to receive FDA clearance for its breast cancertest, MammaPrint(R), which predicts the risk of breast cancer recurrence. Itssecond microarray product, CupPrint(R)*, is a diagnostic test designed toidentify the origin of the primary tumor in "Cancer of Unknown Primary."Agendia also recently presented its new colon cancer prognosis test,ColoPrint(R), which is currently undergoing further validation. Agendiama
